OceanTech Acquisitions I Corp., a blank check company, focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization/similar business combination with one/more businesses. The company was incorporated in 2021 and is based in New York, New York.
IPO Year: 2021
Exchange: NASDAQ
Website: oceantechspac.com
| Date | Price Target | Rating | Analyst |
|---|
Fastest customizable press release news feed in the world
OceanTech Acquisitions I Corp. ("OceanTech" or the "Company") (NASDAQ:OTEC), a special purpose acquisition company, today announced that on May 30, 2023, at the special meeting of the stockholders of the Company, holders of 1,035,788 shares of Class A common stock of the Company (the "Redeeming Stockholders") exercised the right to redeem such shares. On June 2, 2023, the Company made cash payments to the Redeeming Stockholders totaling $11,233,820 representing approximately $10.84 per share. Following such payments to the Redeeming Stockholders, the Company's trust account had a balance of approximately $8,814,443. About OceanTech Acquisitions I Corp. OceanTech is a blank check company
OceanTech Acquisitions I Corp. ("OceanTech" or the "Company") (NASDAQ:OTEC), a special purpose acquisition company, previously filed a definitive proxy statement / final prospectus with respect to a special meeting of its stockholders to be held on Friday, May 26, 2023 at 1:00 p.m. EDT (the "Special Meeting") to vote on, among other things, a proposal to approve an amendment to OceanTech's amended and restated certificate of incorporation to extend the date by which OceanTech must consummate its initial business combination from June 2, 2023 by up to twelve (12) one-month extensions through June 2, 2024, or such earlier date as determined by OceanTech's board of directors. The Company is
Regentis Biomaterials Ltd ("Regentis") is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore the health and enhance quality of life of patients. Regentis' lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into a resorbable implant in the knee for the treatment of painful injuries to articular knee cartilage. There is currently no approved off-the-shelf product marketed in the United States for cartilage repair. GelrinC is already approved as a device with a CE mark in Europe, and Regentis is currently conducting a pivotal trial, under the FDA sanctioned protocol, in the United States and Europe. The transac
OceanTech Acquisitions I Corp. ("OceanTech" or the "Company") (NASDAQ:OTEC), a special purpose acquisition company, today announced that on May 3, 2023 it caused to be deposited $125,000 into the Company's Trust account for its public stockholders, representing $0.067 per public share, allowing the Company to extend the period of time it has to consummate its initial business combination by one month from May 2, 2023 to June 2, 2023 (the "Extension"). The Extension is the sixth of six monthly extensions permitted under the Company's governing documents. View source version on businesswire.com: https://www.businesswire.com/news/home/20230503005554/en/
OceanTech Acquisitions I Corp. ("OceanTech" or the "Company") (NASDAQ:OTEC), a special purpose acquisition company, today announced that on March 28, 2023 it caused to be deposited $125,000 into the Company's Trust account for its public stockholders, representing $0.067 per public share, allowing the Company to extend the period of time it has to consummate its initial business combination by one month from April 2, 2023 to May 2, 2023 (the "Extension"). The Extension is the fifth of six-monthly extensions permitted under the Company's governing documents. Cautionary Statement Regarding Forward-Looking Statements This press release contains statements that constitute "forward-looking sta
OceanTech Acquisitions I Corp. ("OceanTech" or the "Company") (NASDAQ:OTEC), a special purpose acquisition company, today announced that it caused to be deposited $125,000 into the Company's Trust account for its public stockholders, representing $0.067 per public share, allowing the Company to extend the period of time it has to consummate its initial business combination by one month from March 2, 2023 to April 2, 2023 (the "Extension"). The Extension is the fourth of six-monthly extensions permitted under the Company's governing documents. Cautionary Statement Regarding Forward-Looking Statements This press release contains statements that constitute "forward-looking statements," inclu
OceanTech Acquisitions I Corp. ("OceanTech" or the "Company") (NASDAQ:OTEC), a special purpose acquisition company, today announced that its previously announced agreement and plan of merger (the "Merger Agreement") with Majic Wheels Corp. ("Majic Wheels") has been terminated by mutual agreement of all relevant parties. As a result, OceanTech will seek an alternative business combination. About OceanTech Acquisitions I Corp. OceanTech Acquisitions I Corp. is a newly organized blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. OceanTech is sp
OceanTech Acquisitions I Corp. ("OceanTech" or the "Company") (NASDAQ:OTEC), a special purpose acquisition company, today announced that on February 2, 2023 it caused to be deposited $125,000 into the Company's Trust account for its public stockholders, representing $0.067 per public share, allowing the Company to extend the period of time it has to consummate its initial business combination by one month from February 2, 2023 to March 2, 2023 (the "Extension"). The Extension is the third of six-monthly extensions permitted under the Company's governing documents. Cautionary Statement Regarding Forward-Looking Statements This press release contains statements that constitute "forward-look
On December 30, 2022, OceanTech Acquisitions I Corp., a Delaware corporation (the "Company"), caused to be deposited $125,000 into the Company's Trust account for its public stockholders, representing $0.067 per public share, allowing the Company to extend the period of time it has to consummate its initial business combination by one month from January 2, 2022 to February 2, 2023 (the "Extension"). The Extension is the second of six-monthly extensions permitted under the Company's governing documents. Cautionary Statement Regarding Forward-Looking Statements This Press Release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995
On November 29, 2022, OceanTech Acquisitions I Corp. (the "Company" or "OceanTech") (NASDAQ:OTEC), a special purpose acquisition company, announced that its stockholders have approved an extension of the date by which the Company must consummate a business combination from December 2, 2022 to June 2, 2023 (or such earlier date as determined by the Company's board of directors) (the "Extension") at the special meeting of stockholders held on November 29, 2022 (the "Special Meeting"). The Extension provides the Company with additional time to complete the previously announced proposed business combination (the "Transaction") with Majic Wheels Corp., a Wyoming corporation. The Company has dep
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)
3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)
3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)
3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)
3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)
3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)
3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)
3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)
3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)
3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)
425 - OceanTech Acquisitions I Corp. (0001846809) (Subject)
8-K - OceanTech Acquisitions I Corp. (0001846809) (Filer)
425 - OceanTech Acquisitions I Corp. (0001846809) (Subject)
8-K - OceanTech Acquisitions I Corp. (0001846809) (Filer)
425 - OceanTech Acquisitions I Corp. (0001846809) (Subject)
8-K - OceanTech Acquisitions I Corp. (0001846809) (Filer)
424B3 - OceanTech Acquisitions I Corp. (0001846809) (Filer)
EFFECT - OceanTech Acquisitions I Corp. (0001846809) (Filer)
S-4/A - OceanTech Acquisitions I Corp. (0001846809) (Filer)
S-4/A - OceanTech Acquisitions I Corp. (0001846809) (Filer)
Live finance-specific insights
Regentis Biomaterials Ltd ("Regentis") is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore the health and enhance quality of life of patients. Regentis' lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into a resorbable implant in the knee for the treatment of painful injuries to articular knee cartilage. There is currently no approved off-the-shelf product marketed in the United States for cartilage repair. GelrinC is already approved as a device with a CE mark in Europe, and Regentis is currently conducting a pivotal trial, under the FDA sanctioned protocol, in the United States and Europe. The transac
This live feed shows all institutional transactions in real time.
SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)
SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)
SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)
SC 13G - OceanTech Acquisitions I Corp. (0001846809) (Subject)
SC 13G - OceanTech Acquisitions I Corp. (0001846809) (Subject)
SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)
SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)
SC 13G - OceanTech Acquisitions I Corp. (0001846809) (Subject)
SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)
SC 13G - OceanTech Acquisitions I Corp. (0001846809) (Subject)